REVERCE:瑞戈非尼序贯西妥昔单抗对比反向序列治疗经治转移性结直肠癌的随机II期研究
这项随机II期研究纳入101例KRAS第2外显子野生型、氟尿嘧啶类、奥沙利铂和伊立替康治疗失败的转移性结直肠癌患者,比较瑞戈非尼序贯西妥昔单抗(R-C组)与反向序列(C-R组)。R-C组中位总生存期17.4个月 vs C-R组11.6个月(P=0.0293),HR 0.61(95%CI 0.39-0.96)。作者认为瑞戈非尼序贯西妥昔单抗可能较现行标准序列获得更长总生存期。
要点
- R-C组中位OS 17.4个月 vs C-R组11.6个月,HR 0.61(95%CI 0.39-0.96),P=0.0293。
- PFS1的HR 0.97(95%CI 0.61-1.54),PFS2的HR 0.29(95%CI 0.17-0.50)。
- 两臂序贯治疗成功率均为86%,未观察到非预期安全性信号,生活质量评分无显著差异。
核心结论
- 瑞戈非尼序贯西妥昔单抗的治疗序列提示较现行标准序列(西妥昔单抗序贯瑞戈非尼)更长的总生存期。
研究设计与样本
- 随机II期研究,纳入101例KRAS第2外显子野生型、氟尿嘧啶类、奥沙利铂和伊立替康治疗失败的转移性结直肠癌患者。
- 患者随机接受瑞戈非尼序贯西妥昔单抗±伊立替康(R-C组)或反向序列(C-R组)。
- 主要终点为总生存期(OS),关键次要终点包括初始治疗的无进展生存期(PFS1)、第二治疗的无进展生存期(PFS2)、安全性和生活质量。
主要发现
- R-C组中位OS 17.4个月 vs C-R组11.6个月(P=0.0293),HR 0.61(95%CI 0.39-0.96)。
- PFS1(R-C组瑞戈非尼 vs C-R组西妥昔单抗)的HR 0.97(95%CI 0.61-1.54)。
- PFS2(R-C组西妥昔单抗 vs C-R组瑞戈非尼)的HR 0.29(95%CI 0.17-0.50)。
- 两臂序贯治疗成功率均为86%,未观察到非预期安全性信号。
- 整个治疗期间两臂生活质量评分无显著差异;循环生物标志物分析显示RAS、BRAF、EGFR、HER2和MET的新发致癌性改变在西妥昔单抗治疗后较瑞戈非尼治疗后更常检测到。
关键数值与推荐
- 主要终点OS:R-C组中位17.4个月 vs C-R组11.6个月,P=0.0293,HR 0.61(95%CI 0.39-0.96)。
- PFS1的HR 0.97(95%CI 0.61-1.54);PFS2的HR 0.29(95%CI 0.17-0.50)。
- 两臂序贯治疗成功率均为86%。
临床怎么用
- 原文结论未据此给出具体临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The objective of this randomized phase II trial was to evaluate efficacy and safety of the therapeutic sequence of regorafenib followed by cetuximab, compared with cetuximab followed by regorafenib, as the current standard sequence for metastatic colorectal cancer patients. PATIENTS AND METHODS: Patients with KRAS exon 2 wild-type metastatic colorectal cancer after failure of fluoropyrimidine, oxaliplatin, and irinotecan were randomized to receive sequential treatment with regorafenib followed by cetuximab ± irinotecan (R-C arm), or the reverse sequence [cetuximab ± irinotecan followed by regorafenib (C-R arm)]. The primary end point was overall survival (OS). Key secondary end points included progression-free survival (PFS) with initial treatment (PFS1), PFS with second treatment (PFS2), safety, and quality of life. Exploratory end points included serial biomarker analyses, including oncogenic alterations from circulating tumor DNA or multiple serum or plasma proteins. RESULTS: One-hundred one patients were randomized and eligible for efficacy analysis. Sequential treatment was successful in 86% patients in both arms. Median OS for R-C and C-R was 17.4 and 11.6 months, respectively (P = 0.0293), with a hazard ratio (HR) of 0.61 for OS [95% confidence interval (CI) 0.39-0.96]. The HR for PFS1 (regorafenib in R-C versus cetuximab in C-R) was 0.97 (95% CI 0.61-1.54), and PFS2 (C in R-C versus R in C-R) was 0.29 (95% CI 0.17-0.50). No unexpected safety signals were observed. The quality of life scores during the entire treatment period was not significantly different between the two arms. Circulating biomarker analyses showed emerging oncogenic alterations in RAS, BRAF, EGFR, HER2, and MET, which were more commonly detected after cetuximab than after regorafenib. CONCLUSIONS: The therapeutic sequence of regorafenib followed by cetuximab suggests a longer OS than the current standard sequence.
引用
- Shitara K, Yamanaka T, Denda T, et al. REVERCE: a randomized phase II study of regorafenib followed by cetuximab versus the reverse sequence for previously treated metastatic colorectal cancer patients. Ann Oncol. 2019. PMID: 30508156. doi:10.1093/annonc/mdy526
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。